HomeCompareALTA vs ABBV

ALTA vs ABBV: Dividend Comparison 2026

ALTA yields 6.45% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ALTA wins by $1727.02M in total portfolio value
10 years
ALTA
ALTA
● Live price
6.45%
Share price
$44.16
Annual div
$2.85
5Y div CAGR
86.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1727.13M
Annual income
$1,631,027,971.02
Full ALTA calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — ALTA vs ABBV

📍 ALTA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodALTAABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ALTA + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ALTA pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ALTA
Annual income on $10K today (after 15% tax)
$548.57/yr
After 10yr DRIP, annual income (after tax)
$1,386,373,775.37/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ALTA beats the other by $1,386,352,719.36/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ALTA + ABBV for your $10,000?

ALTA: 50%ABBV: 50%
100% ABBV50/50100% ALTA
Portfolio after 10yr
$863.61M
Annual income
$815,526,371.39/yr
Blended yield
94.43%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

ALTA
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ALTA buys
0
ABBV buys
0
No recent congressional trades found for ALTA or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricALTAABBV
Forward yield6.45%3.06%
Annual dividend / share$2.85$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR86.8%40.6%
Portfolio after 10y$1727.13M$102.3K
Annual income after 10y$1,631,027,971.02$24,771.77
Total dividends collected$1720.17M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ALTA vs ABBV ($10,000, DRIP)

YearALTA PortfolioALTA Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,906$1,205.57$11,550$430.00+$356.00ALTA
2$15,245$2,505.74$13,472$627.96+$1.8KALTA
3$21,913$5,601.42$15,906$926.08+$6.0KALTA
4$37,504$14,056.55$19,071$1,382.55+$18.4KALTA
5$82,128$41,999.04$23,302$2,095.81+$58.8KALTA
6$248,441$160,564.48$29,150$3,237.93+$219.3KALTA
7$1,113,792$847,959.89$37,536$5,121.41+$1.08MALTA
8$7,828,402$6,636,643.99$50,079$8,338.38+$7.78MALTA
9$89,811,282$81,434,891.80$69,753$14,065.80+$89.74MALTA
10$1,727,126,042$1,631,027,971.02$102,337$24,771.77+$1727.02MALTA

ALTA vs ABBV: Complete Analysis 2026

ALTAStock

Altabancorp operates as the bank holding company for Altabank, a state-chartered bank that provides retail and commercial banking products and services. The company accepts various deposits, such as checking, rewards checking, savings, and money market deposit accounts, as well as individual retirement accounts and certificates of deposit. Its loan products include commercial and residential real estate lending comprising acquisition and development loans, construction loans, and mortgage financing; commercial and industrial loans; consumer loans consisting of home equity loans, home improvement loans, automobile loans, debt consolidation loans, and general consumer lending; and SBA loans. The company also offers credit and debit cards; investment securities, such as U.S. Agency issues, mortgage-backed securities, and municipal bonds; and mobile and Internet banking, automatic teller machine, treasury management, remote deposit capture, bill pay, cashier's checks, money orders, and safe deposit services. It serves real estate developers and contractors, small to medium sized businesses, individuals, and professionals and professional firms through 26 retail branches located in Utah and southern Idaho. The company was formerly known as People's Utah Bancorp and changed its name to Altabancorp in July 2020. Altabancorp was founded in 1905 and is headquartered in American Fork, Utah.

Full ALTA Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this ALTA vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ALTA vs SCHDALTA vs JEPIALTA vs OALTA vs KOALTA vs MAINALTA vs JNJALTA vs MRKALTA vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.